JP2014527042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014527042A5 JP2014527042A5 JP2014522877A JP2014522877A JP2014527042A5 JP 2014527042 A5 JP2014527042 A5 JP 2014527042A5 JP 2014522877 A JP2014522877 A JP 2014522877A JP 2014522877 A JP2014522877 A JP 2014522877A JP 2014527042 A5 JP2014527042 A5 JP 2014527042A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- acute lymphoblastic
- hydrate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 4
- 208000036566 Erythroleukaemia Diseases 0.000 claims 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 4
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161512016P | 2011-07-27 | 2011-07-27 | |
| US61/512,016 | 2011-07-27 | ||
| US201161560486P | 2011-11-16 | 2011-11-16 | |
| US61/560,486 | 2011-11-16 | ||
| PCT/US2012/047100 WO2013016081A1 (en) | 2011-07-27 | 2012-07-18 | Notch pathway signaling inhibitor compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014527042A JP2014527042A (ja) | 2014-10-09 |
| JP2014527042A5 true JP2014527042A5 (enExample) | 2015-08-20 |
| JP6027110B2 JP6027110B2 (ja) | 2016-11-16 |
Family
ID=46598983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014522877A Active JP6027110B2 (ja) | 2011-07-27 | 2012-07-18 | ノッチ経路シグナリングインヒビター化合物 |
Country Status (36)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10350216B2 (en) | 2013-01-14 | 2019-07-16 | The Trustees Of Columbia University In The City Of New York | Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders |
| KR20160104612A (ko) | 2013-07-26 | 2016-09-05 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조성물 |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| TWI609687B (zh) * | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| JO3491B1 (ar) * | 2015-07-07 | 2020-07-05 | Audion Therapeutics | مركبات مثبطة لإشارات مسار notch |
| AU2017213628B2 (en) | 2016-02-05 | 2021-07-29 | Denali Therapeutics Inc. | Inhibitors of receptor-interacting protein kinase 1 |
| AU2017233898B2 (en) | 2016-03-15 | 2022-12-15 | Oryzon Genomics, S.A. | Combinations of LSD1 inhibitors for use in the treatment of solid tumors |
| WO2017180385A1 (en) | 2016-04-12 | 2017-10-19 | Eli Lilly And Company | Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer |
| MX380779B (es) * | 2016-04-12 | 2025-03-12 | Lilly Co Eli | Terapia combinatoria con inhibidores notch y cdk4/6 |
| JP7194022B2 (ja) * | 2016-05-20 | 2022-12-21 | イーライ リリー アンド カンパニー | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 |
| US20190209581A1 (en) | 2016-08-31 | 2019-07-11 | Eli Lilly And Company | Dosage regimen for treatment of solid tumors |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| WO2018107060A1 (en) | 2016-12-09 | 2018-06-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| AU2018222749B2 (en) | 2017-02-17 | 2024-04-18 | Fred Hutchinson Cancer Center | Combination therapies for treatment of BCMA-related cancers and autoimmune disorders |
| EP3703750B1 (en) | 2017-11-01 | 2024-12-04 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides |
| MA50564A (fr) * | 2017-11-06 | 2020-09-16 | Hutchinson Fred Cancer Res | Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase |
| MX2020011826A (es) * | 2018-05-06 | 2021-01-15 | Ayala Pharmaceuticals Inc | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. |
| JP2022504265A (ja) | 2018-10-02 | 2022-01-13 | フリークエンシー セラピューティクス インコーポレイテッド | 耳治療薬に関する医薬組成物及び方法 |
| US20220175776A1 (en) | 2019-04-08 | 2022-06-09 | Frequency Therapeutics, Inc. | Combination of chir99021 and valproic acid for treating hearing loss |
| EP4463229A1 (en) | 2022-01-12 | 2024-11-20 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0001232A3 (en) * | 1996-12-23 | 2001-02-28 | Elan Pharmaceuticals Inc San F | Cycloalkyl, lactam, lactone derivatives and their thio analogues inhibiting betha-amyloid peptide release and/or its synthesis and pharmaceutical compositions containing the compounds |
| AU4710199A (en) * | 1998-06-22 | 2000-01-10 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
| CA2324474A1 (en) | 1998-06-22 | 1999-12-29 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
| NZ541324A (en) | 2003-02-04 | 2008-10-31 | Hoffmann La Roche | Malonamide derivatives as gamma-secretase inhibitors |
| KR100834177B1 (ko) | 2003-09-09 | 2008-05-30 | 에프. 호프만-라 로슈 아게 | 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체 |
| DK1673347T3 (en) | 2003-10-06 | 2015-10-12 | Hoffmann La Roche | SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USED AS GAMMA SECRETASE INHIBITORS |
| AU2007229550B2 (en) | 2006-03-27 | 2012-03-08 | F. Hoffmann-La Roche Ag | Malonamide derivatives as gamma secretase inhibitors |
| CA2676160A1 (en) * | 2007-02-02 | 2008-08-07 | F. Hoffmann-La Roche Ag | 6-oxo-6,7-dihydro-5h-dibenzo[b,d]azepin-7-yl derivatives |
| US20090181944A1 (en) | 2008-01-11 | 2009-07-16 | John Frederick Boylan | Method for cancer therapy |
| US8637493B2 (en) * | 2009-11-12 | 2014-01-28 | University Of Massachusetts | Methods for treating glioblastoma |
-
2012
- 2012-07-10 JO JOP/2012/0190A patent/JO3148B1/ar active
- 2012-07-10 AR ARP120102486A patent/AR087107A1/es not_active Application Discontinuation
- 2012-07-13 TW TW101125459A patent/TWI568730B/zh active
- 2012-07-18 CA CA2841178A patent/CA2841178C/en active Active
- 2012-07-18 PT PT127411924T patent/PT2736920E/pt unknown
- 2012-07-18 AU AU2012287251A patent/AU2012287251B2/en active Active
- 2012-07-18 PE PE2014000129A patent/PE20141061A1/es active IP Right Grant
- 2012-07-18 DK DK12741192.4T patent/DK2736920T3/en active
- 2012-07-18 US US13/551,681 patent/US8569286B2/en active Active
- 2012-07-18 MY MYPI2014700183A patent/MY184303A/en unknown
- 2012-07-18 HU HUE12741192A patent/HUE027534T2/en unknown
- 2012-07-18 ES ES12741192.4T patent/ES2544937T3/es active Active
- 2012-07-18 PL PL12741192T patent/PL2736920T3/pl unknown
- 2012-07-18 AP AP2014007362A patent/AP4080A/en active
- 2012-07-18 MX MX2014001084A patent/MX356536B/es active IP Right Grant
- 2012-07-18 ME MEP-2015-105A patent/ME02171B/me unknown
- 2012-07-18 SI SI201230246T patent/SI2736920T1/sl unknown
- 2012-07-18 RS RS20150496A patent/RS54135B1/sr unknown
- 2012-07-18 JP JP2014522877A patent/JP6027110B2/ja active Active
- 2012-07-18 WO PCT/US2012/047100 patent/WO2013016081A1/en not_active Ceased
- 2012-07-18 HR HRP20150771TT patent/HRP20150771T1/hr unknown
- 2012-07-18 KR KR1020147001731A patent/KR101578309B1/ko active Active
- 2012-07-18 PH PH1/2014/500215A patent/PH12014500215B1/en unknown
- 2012-07-18 BR BR112014001600-3A patent/BR112014001600B1/pt active IP Right Grant
- 2012-07-18 EA EA201490161A patent/EA023044B1/ru not_active IP Right Cessation
- 2012-07-18 EP EP12741192.4A patent/EP2736920B1/en active Active
- 2012-07-18 CN CN201280037471.9A patent/CN103732612B/zh active Active
-
2013
- 2013-12-17 IL IL229988A patent/IL229988A/en active IP Right Grant
-
2014
- 2014-01-22 MA MA36712A patent/MA35611B1/fr unknown
- 2014-01-22 DO DO2014000011A patent/DOP2014000011A/es unknown
- 2014-01-23 CL CL2014000175A patent/CL2014000175A1/es unknown
- 2014-01-24 CO CO14014585A patent/CO6862159A2/es active IP Right Grant
- 2014-01-24 CR CR20140036A patent/CR20140036A/es unknown
- 2014-01-24 GT GT201400012A patent/GT201400012A/es unknown
- 2014-01-27 EC ECSP14013179 patent/ECSP14013179A/es unknown
-
2015
- 2015-08-25 CY CY20151100742T patent/CY1116645T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014527042A5 (enExample) | ||
| JP2020511467A5 (enExample) | ||
| ME02171B (me) | Spoj za inhibiciju notch signalnog puta | |
| JP2013509429A5 (enExample) | ||
| JP2015536964A5 (enExample) | ||
| JP2017519027A5 (enExample) | ||
| JP2014502638A5 (enExample) | ||
| JP2014509653A5 (enExample) | ||
| JP2013237682A5 (enExample) | ||
| JP2015500331A5 (enExample) | ||
| JP2013522326A5 (enExample) | ||
| FI3328827T3 (fi) | Glutamiinianalogien aihiolääkkeitä | |
| JP2018024682A5 (enExample) | ||
| JP2015509536A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| HRP20171151T1 (hr) | Inhibitori cdc7 | |
| JP2017525730A5 (enExample) | ||
| HRP20202065T1 (hr) | Kristalni oblik inhibitora mdm2 | |
| JP2013522232A5 (enExample) | ||
| HRP20160545T1 (hr) | Inhibitor fosfoinozitid 3-kinaze sa dijelom koji veže cink | |
| JP2015522037A5 (enExample) | ||
| JP2012526766A5 (enExample) | ||
| JP2015193630A5 (enExample) | ||
| JP2014530818A5 (enExample) |